Good Samaritan Hospital
Cincinnati, Ohio, 45220, United States
NCT Number: NCT03113656
Infants with neonatal abstinence syndrome (NAS) who are cared for in a Neonatal Intensive Care Unit (NICU) often display symptoms including hyperactivity, irritability, jitteriness, poor feeding, and poor sleep patterns. The recommended first line of treatment to relieve these symptoms involves nonpharmacological interventions. The purpose of the current pilot study is to provide preliminary data to assist in the design of a larger scale study to examine one nonpharmacological intervention, weighted blankets. The pilot study will assess the feasibility of a cross-over randomized controlled design to study the impact of a weighted blanket on infants' symptoms of NAS.
The aims of the study are:
Aim1: To determine the feasibility of recruiting patients for a study evaluating the use of weighted blankets in the care of infants with NAS Aim 2: To determine the feasibility and safety of the study procedures Aim 3: To examine whether there is clinical benefit to using weighted blankets for the treatment of symptoms in infants with NAS.
After informed consent is obtained, infants will be randomized to have either a weighted blanket or a non-weighted blanket placed on them first. A cross-over design will be used so all infants will experience both the non-weighted and weighted blankets. Thirty minutes before each feeding, baseline vital signs and Finnegan score will be obtained. Then, a blanket (weighted or non-weighted) will be placed on the infant for 30 minutes. Infants will be directly monitored and on heart rate/respiratory rate monitors while the blanket is applied. Vital signs and Finnegan scores will be obtained at the end of 30 minutes of blanket placement, infants will be fed, and vital signs and Finnegan scores will be obtained again 30 minutes after the blanket was removed. Descriptive statistics will be used to determine the enrollment rate and feasibility of the protocol. Nonparametric statistics will be used to compare total Finnegan scores for infants with the weighted blanket applied compared to infants with a non-weighted blanket applied. Changes in Finnegan scores will be examined to estimate an effect size to use in a power analysis for a future larger effectiveness study.
Looking for future studies?
Notify Me37 week and older
All sexes
Interventional
Not applicable
Cincinnati, Ohio, 45220, United States
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Weighted blanket placed on infant for 30 minutes
Non-Weighted blanket placed on infant for 30 minutes
Time frame: baseline and 30 minutes
Finnegan scale measures signs of neonatal drug withdrawal syndrome. It provides a summative score obtained from the assessment of 21 items related to neonatal withdrawal. The total score ranges from 0 to 43 with a higher score indicating more severe symptoms. Values above 8 have been described as being indicative of neonatal abstinence syndrome.
TriHealth Inc.
Other
The Use of Weighted Blankets in the Care of Infants With Neonatal Abstinence Syndrome (NAS)
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04419857
Chemically-Induced Disorders, Congenital, Hereditary, and Neonatal Diseases and Abnormalities
New Haven, Connecticut, United States
View Trial DetailsNCT03918850
Chemically-Induced Disorders, Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Jacksonville, Florida, United States
View Trial DetailsNCT03911739
Chemically-Induced Disorders, Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Jacksonville, Florida, United States
View Trial DetailsNCT03911466
Chemically-Induced Disorders, Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Jacksonville, Florida, United States
View Trial Details